WO2005027848A3 - Methods for screening osteogenic compounds targeting syk kinase and/or vav3 and uses of syk modulators and/or vav modulators - Google Patents

Methods for screening osteogenic compounds targeting syk kinase and/or vav3 and uses of syk modulators and/or vav modulators Download PDF

Info

Publication number
WO2005027848A3
WO2005027848A3 PCT/US2004/030622 US2004030622W WO2005027848A3 WO 2005027848 A3 WO2005027848 A3 WO 2005027848A3 US 2004030622 W US2004030622 W US 2004030622W WO 2005027848 A3 WO2005027848 A3 WO 2005027848A3
Authority
WO
WIPO (PCT)
Prior art keywords
vav3
syk
pathway
methods
compounds
Prior art date
Application number
PCT/US2004/030622
Other languages
French (fr)
Other versions
WO2005027848A2 (en
Inventor
Steven L Teitelbaum
Frederick P Ross
Roberta Faccio
Wei Zhou
Wojciech A Swat
Original Assignee
Barnes Jewish Hospital
Steven L Teitelbaum
Frederick P Ross
Roberta Faccio
Wei Zhou
Wojciech A Swat
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Barnes Jewish Hospital, Steven L Teitelbaum, Frederick P Ross, Roberta Faccio, Wei Zhou, Wojciech A Swat filed Critical Barnes Jewish Hospital
Publication of WO2005027848A2 publication Critical patent/WO2005027848A2/en
Publication of WO2005027848A3 publication Critical patent/WO2005027848A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0654—Osteocytes, Osteoblasts, Odontocytes; Bones, Teeth
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/999—Small molecules not provided for elsewhere

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Veterinary Medicine (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Rheumatology (AREA)
  • Microbiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Methods for screening osteogenic compounds, particularly compounds which result in net bone formation, including compounds which modulate osteoclast differentiation and function, using the Syk kinase pathway and/or the Vav3 pathway. The present invention relates particularly to methods for screening osteogenic compounds using the Dap12/Syk complex, Syk kinase or the Syk kinase pathway, the Vav pathway, Vav3, or the Vav3 pathway. The invention also provides methods and compositions for modulating the processes of bone formation and/or bone loss, thereby providing novel treatments for bone diseases. The present invention encompasses compounds identified by such screening methods and compositions comprising these compounds. The invention also provides methods for enhancing processes of bone formation, comprise administering compounds or agents which modulate, particularly inhibit, Syk kinase, Vav3 or the Syk kinase pathway or Vav3 pathway.
PCT/US2004/030622 2003-09-19 2004-09-20 Methods for screening osteogenic compounds targeting syk kinase and/or vav3 and uses of syk modulators and/or vav modulators WO2005027848A2 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US50440403P 2003-09-19 2003-09-19
US60/504,404 2003-09-19
US50595203P 2003-09-25 2003-09-25
US60/505,952 2003-09-25

Publications (2)

Publication Number Publication Date
WO2005027848A2 WO2005027848A2 (en) 2005-03-31
WO2005027848A3 true WO2005027848A3 (en) 2005-05-19

Family

ID=34381120

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2004/030622 WO2005027848A2 (en) 2003-09-19 2004-09-20 Methods for screening osteogenic compounds targeting syk kinase and/or vav3 and uses of syk modulators and/or vav modulators

Country Status (1)

Country Link
WO (1) WO2005027848A2 (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8557806B2 (en) 2002-07-29 2013-10-15 Rigel Pharmaceuticals, Inc. Methods of treating or preventing autoimmune diseases with 2,4-pyrimidinediamine compounds
US8835430B2 (en) 2002-02-01 2014-09-16 Rigel Pharmaceuticals, Inc. 2,4-pyrimidinediamine compounds and their uses

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102358738A (en) 2003-07-30 2012-02-22 里格尔药品股份有限公司 2,4-pyrimidinediamine compounds and uses of treating or preventing autoimmune diseases thereof
WO2006068770A1 (en) 2004-11-24 2006-06-29 Rigel Pharmaceuticals, Inc. Spiro-2, 4-pyrimidinediamine compounds and their uses
US8227455B2 (en) 2005-04-18 2012-07-24 Rigel Pharmaceuticals, Inc. Methods of treating cell proliferative disorders
WO2006135915A2 (en) 2005-06-13 2006-12-21 Rigel Pharmaceuticals, Inc. Methods and compositions for treating degenerative bone disorders
CA2691618A1 (en) * 2007-06-29 2009-01-08 Schering Corporation Mdl-1 uses
US20130310387A1 (en) 2012-05-16 2013-11-21 Novartis Ag Monocyclic Heteroaryl Cycloalkyldiamine Derivatives

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030158195A1 (en) * 2001-12-21 2003-08-21 Cywin Charles L. 1,6 naphthyridines useful as inhibitors of SYK kinase

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030158195A1 (en) * 2001-12-21 2003-08-21 Cywin Charles L. 1,6 naphthyridines useful as inhibitors of SYK kinase

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
BRANCH ET AL.: "A good antisense molecule is hard to find", TIBS, vol. 23, 2000, pages 45 - 50, XP004108000, DOI: doi:10.1016/S0968-0004(97)01155-9 *
COSTELLO ET AL.: "The Rho-family GTP exchange factor Vav is a critical transducer of T cell receptor signals to the calcium, ERK, and NF-kB pathways", PROC. NATL. ACAD. SCI. USA, vol. 96, 1999, pages 3035 - 3040 *
CROOKE ET AL.: "Basic principles of antisense therapeutics", 1998, pages: 1 - 50 *
GREEN ET AL.: "Antisense oligonucleotides L and evolving technology for the odulation of gene expression in human diseases", vol. 191, 2000, pages 93 - 105 *
JEN ET AL.: "Suppression of gene expression by targeted disruption of messenger RNA: available options and current strategies", STEM CELLS, vol. 18, 2000, pages 307 - 319, XP002181426, DOI: doi:10.1634/stemcells.18-5-307 *
MARZIA ET AL.: "Decreased c-Src expression enhances osteobast differentiation and bone formation", JOURNAL OF CELL BIOLOGY, vol. 151, 2002, pages 311 - 320 *
YAMAMOTO ET AL.: "Development of a high-throughput fluoroimmunoassay for Syk kinase and Syk kinase inhibitors", ANALYTICAL BIOCHEMISTRY, vol. 215, 2003, pages 256 - 261, XP055143651, DOI: doi:10.1016/S0003-2697(03)00026-5 *

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8835430B2 (en) 2002-02-01 2014-09-16 Rigel Pharmaceuticals, Inc. 2,4-pyrimidinediamine compounds and their uses
US9018204B1 (en) 2002-02-01 2015-04-28 Rigel Pharmaceuticals, Inc. 2,4-pyrimidinediamine compounds and their uses
US9346765B2 (en) 2002-02-01 2016-05-24 Rigel Pharmaceuticals, Inc. 2,4-pyrimidinediamine compounds and their uses
US9416112B2 (en) 2002-02-01 2016-08-16 Rigel Pharmaceuticals, Inc. 2,4-pyrimidinediamine compounds and their uses
US9913842B2 (en) 2002-02-01 2018-03-13 Rigel Pharmaceuticals, Inc. 2,4-pyrimidinediamine compounds and their uses
US8557806B2 (en) 2002-07-29 2013-10-15 Rigel Pharmaceuticals, Inc. Methods of treating or preventing autoimmune diseases with 2,4-pyrimidinediamine compounds

Also Published As

Publication number Publication date
WO2005027848A2 (en) 2005-03-31

Similar Documents

Publication Publication Date Title
WO2004073653A3 (en) Methods for treating pain by administering a nerve growth factor antagonist and an nsaid and compositions containing the same
WO2004080377A3 (en) Kcnq channel modulating compounds and their pharmaceutical use
HK1092467A1 (en) N-alkyl-hydroxamic acid-isoindolyl compounds and their pharmaceutical uses n-
WO2001085664A3 (en) Compounds and methods for regulating bacterial growth and pathogenesis
MX2010002674A (en) Gamma secretase modulators.
WO2005009389A3 (en) Anaplastic lymphoma kinase modulators and methods of use
WO2009076454A3 (en) Compounds that modulate intracellular calcium
WO2009035818A8 (en) Compounds that modulate intracellular calcium
WO2005028678A3 (en) Methods and materials for identifying agents which modulate bone remodeling and agents identified thereby
WO2008097541A3 (en) Variants derived from actriib and uses therefor
MX2010006379A (en) Gamma secretase modulators.
CA2514473A1 (en) Fused bicyclic nitrogen-containing heterocycles
WO2006014325A3 (en) C-met modulators and method of use
CA2492096A1 (en) Cis-alkoxy-substituted spirocyclic 1-h-pyrrolidine-2,4-dione derivatives serving as pesticides
WO2007076085A3 (en) Fused pyrimidones and thiopyrimidones, and uses thereof
WO2004009062A3 (en) NMDA RECEPTOR ANTAGONISTS AND THEIR USE IN INHIBITING ABNORMAL HYPERPHOSPHORYLATION OF MICROTUBULE ASSOCIATED PROTEIN tau
MX2010005028A (en) Gamma secretase modulators.
WO2003068944A3 (en) METHODS AND COMPOSITION FOR MODULATING TYPE I MUSCLE FORMATION USING PGC-1α-
WO2005027848A3 (en) Methods for screening osteogenic compounds targeting syk kinase and/or vav3 and uses of syk modulators and/or vav modulators
WO2007067737A3 (en) Methods and compositions for inhibiting hiv infection
WO2005007123A3 (en) Pin1-modulating compounds and methods of use thereof
WO2006116503A3 (en) Methods and compositions for modulating wnt signaling pathway
WO2004083235A3 (en) Tie-2 modulators and methods of use
MX2010001501A (en) Gamma secretase modulators.
TW200738244A (en) 20-Alkyl, gemini vitamin D3 compounds and methods of use thereof

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BW BY BZ CA CH CN CO CR CU CZ DK DM DZ EC EE EG ES FI GB GD GE GM HR HU ID IL IN IS JP KE KG KP KZ LC LK LR LS LT LU LV MA MD MK MN MW MX MZ NA NI NO NZ PG PH PL PT RO RU SC SD SE SG SK SY TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SZ TZ UG ZM ZW AM AZ BY KG MD RU TJ TM AT BE BG CH CY DE DK EE ES FI FR GB GR HU IE IT MC NL PL PT RO SE SI SK TR BF CF CG CI CM GA GN GQ GW ML MR SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase